{"title":"'Perspectives of pulmonologists and thoracic surgeons on Oligometastatic disease: curability, treatment approaches, and disease trajectory'.","authors":"Damla Azaklı, Inanc Yazici, Aysegul Erinc, Celal Satici","doi":"10.1080/14796694.2025.2504786","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Oligometastatic disease (OMD) is defined by a limited number of metastases, affecting treatment strategies and prognosis. This study evaluates the perspectives of pulmonologists and thoracic surgeons on the curability, treatment approaches, and disease trajectory of synchronous OMD, oligorecurrence, and oligoprogression.</p><p><strong>Methods: </strong>A survey was conducted among pulmonologists, thoracic surgeons, and trainees at Yedikule Chest Disease and Thoracic Surgery Research and Training Hospital. Participants provided views on OMD's curability, treatment preferences, and confidence in discussing prognosis using Likert scales. Data were analyzed using descriptive statistics and comparative methods.</p><p><strong>Results: </strong>Of 160 contacted participants, 60 (37.5%) completed the survey. Most respondents (86.6%) regarded synchronous OMD as curable, with 65% for oligorecurrence and only 23.4% for oligoprogression. Confidence in understanding synchronous OMD's trajectory significantly differed, with attending physicians at 67.9% versus trainees at 43.8% (<i>p</i> < 0.05). Thoracic surgeons had higher confidence in oligorecurrence (88.3%) than pulmonologists (46%, <i>p</i> < 0.05). A preference for combined systemic and local therapies was noted: 73.3% for synchronous OMD, 75% for oligorecurrence, and 78.4% for oligoprogression.</p><p><strong>Conclusion: </strong>The study reveals diverse perspectives on OMD, highlighting the need for multidisciplinary collaboration and ongoing education to improve understanding and management of the disease.</p>","PeriodicalId":12672,"journal":{"name":"Future oncology","volume":" ","pages":"1849-1857"},"PeriodicalIF":3.0000,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12150625/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Future oncology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/14796694.2025.2504786","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/5/12 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Background: Oligometastatic disease (OMD) is defined by a limited number of metastases, affecting treatment strategies and prognosis. This study evaluates the perspectives of pulmonologists and thoracic surgeons on the curability, treatment approaches, and disease trajectory of synchronous OMD, oligorecurrence, and oligoprogression.
Methods: A survey was conducted among pulmonologists, thoracic surgeons, and trainees at Yedikule Chest Disease and Thoracic Surgery Research and Training Hospital. Participants provided views on OMD's curability, treatment preferences, and confidence in discussing prognosis using Likert scales. Data were analyzed using descriptive statistics and comparative methods.
Results: Of 160 contacted participants, 60 (37.5%) completed the survey. Most respondents (86.6%) regarded synchronous OMD as curable, with 65% for oligorecurrence and only 23.4% for oligoprogression. Confidence in understanding synchronous OMD's trajectory significantly differed, with attending physicians at 67.9% versus trainees at 43.8% (p < 0.05). Thoracic surgeons had higher confidence in oligorecurrence (88.3%) than pulmonologists (46%, p < 0.05). A preference for combined systemic and local therapies was noted: 73.3% for synchronous OMD, 75% for oligorecurrence, and 78.4% for oligoprogression.
Conclusion: The study reveals diverse perspectives on OMD, highlighting the need for multidisciplinary collaboration and ongoing education to improve understanding and management of the disease.
期刊介绍:
Future Oncology (ISSN 1479-6694) provides a forum for a new era of cancer care. The journal focuses on the most important advances and highlights their relevance in the clinical setting. Furthermore, Future Oncology delivers essential information in concise, at-a-glance article formats - vital in delivering information to an increasingly time-constrained community.
The journal takes a forward-looking stance toward the scientific and clinical issues, together with the economic and policy issues that confront us in this new era of cancer care. The journal includes literature awareness such as the latest developments in radiotherapy and immunotherapy, concise commentary and analysis, and full review articles all of which provide key findings, translational to the clinical setting.